XT-150 is under clinical development by Xalud Therapeutics and currently in Phase II for Neuropathic Pain (Neuralgia). According to GlobalData, Phase II drugs for Neuropathic Pain (Neuralgia) have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XT-150’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XT-150 is under development for the treatment of neuropathic pain, multiple sclerosis, degenerative disc disease, facet syndrome, osteoarthritis, osteoarthritis pain, amyotrophic lateral sclerosis, unspecified dermatological disorders, unspecified ophthalmological disorders and unspecified gastrointestinal disorders. It is administered through the intraarticular and intrathecal route. The drug candidate is a non-viral vector-based gene therapy that comprises of a combination of plasmid DNA nucleic acid expressing IL-10 protein and a compound that improves the uptake of the plasmid into cells. It was also under development for the treatment of chemotherapy-induced peripheral neuropathy, thermal analgesia.
Xalud Therapeutics overview
Xalud Therapeutics provides healthcare services. The company develops novel therapies for the treatment of neuro-inflammatory diseases such as neuropathic pain, multiple sclerosis, and amyotrophic lateral sclerosis. It is headquartered in San Francisco, California, United States.
For a complete picture of XT-150’s drug-specific PTSR and LoA scores, buy the report here.